Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Active ingredients: cyclophosphamide
What it is used for
Frequently responsive myeloproliferative and lymphoproliferative disorders: Malignant lymphomas including Hodgkins (Stages III and IV, Peter's Staging System*) and non-Hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease). *Modified as the International Staging Classification for Hodgkin's Disease in 'Report of the Committee on the Staging of Hodgkin's Disease'. Cancer Res 26: 1310, 1966. Stage I. Disease limited to one anatomic region (Stage I) or two contiguous anatomic regions (Stage I2) on the same side of the diaphragm. Stage II. Disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm. Stage III. Disease on both sides of the diaphragm but not extending beyond the involvement of lymph nodes, spleen and/or Waldeyer's ring. Stage IV. Involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or Waldeyer's ring. All stages are subclassified as A or B to indicate the absence or presence, respectively, of systemic symptoms. Frequently responsive solid malignancies: Neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma. Infrequently responsive malignancies: Carcinoma of the breast; malignant neoplasms of the lung. Immunosuppressive properties: Cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. Wegener's granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. Cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Intravenous
- Store below 25 degrees Celsius
- Protect from Light
- Shelf lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
White crystalline substance
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient cyclophosphamide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Endoxan Powder for injection - myDr.com.au
Endoxan Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Idiopathic retroperitoneal fibrosis - myDr.com.au
Idiopathic retroperitoneal fibrosis is a rare inflammatory condition that can lead to abdominal pain and kidney failure.
Read more on myDr website
Chemotherapy | myVMC
Chemotherapry treatment and side effects information on chemotherapy and cancer drug medical treatment news.
Read more on myVMC – Virtual Medical Centre website